Introduction
Vasomotor symptoms, particularly hot flashes and night sweats, are among the most common and troublesome manifestations of menopause. They result from estrogen decline, which disrupts hypothalamic thermoregulation and leads to exaggerated heat-dissipation responses. For many women, these symptoms are moderate to severe and significantly impair quality of life, affecting sleep, daily functioning, and overall well-being.
Although hormone replacement therapy remains the most effective treatment, its use is limited by an unfavourable benefit–risk profile in certain populations, especially women over 60 years of age or those with contraindications such as cardiovascular disease, liver disorders, unexplained bleeding, or hormone-sensitive malignancies. This creates a clear need for effective non-hormonal therapies.
A key recent advance has been the identification of hypothalamic KNDy neurons as central regulators of thermoregulation. Estrogen deficiency increases neurokinin B signalling in these neurons, promoting thermoregulatory instability. This has led to the development of neurokinin receptor antagonists as targeted treatments for vasomotor symptoms.
Neurokinin receptor antagonists as a novel strategy in menopausal vasomotor symptoms
Elinzanetant exemplifies this new approach. It is a dual antagonist of NK‑1 and NK‑3 receptors, thereby modulating both neurokinin B–mediated excitation and substance P–related pathways. This dual action is thought not only to stabilize thermoregulation but also to improve sleep, which is often disturbed in menopausal women. Clinical trials have demonstrated significant and sustained reductions in hot flash frequency, along with improvements in sleep quality and quality of life. The drug is generally well tolerated, with the most common adverse effects being somnolence, fatigue, and headache, and without evidence of hepatotoxicity or endometrial stimulation.
Importantly, elinzanetant has also shown efficacy in women receiving endocrine therapy for hormone receptor–positive breast cancer, where hormonal options are contraindicated, highlighting its relevance in difficult-to-treat populations.
This compound belongs to a broader emerging class of neurokinin receptor antagonists. The most established agent is fezolinetant, a selective NK‑3 antagonist that directly targets neurokinin B signalling and has demonstrated rapid and clinically meaningful symptom relief. Earlier compounds such as pavinetant showed similar efficacy but raised concerns about liver safety, underlining the importance of careful pharmacovigilance in this class.
Ongoing research is exploring newer agents and combination approaches aimed at optimizing efficacy, tolerability, and central effects. Overall, neurokinin receptor antagonists represent a shift toward mechanism-based, non-hormonal therapy, offering an important alternative for women who cannot or do not wish to use hormone treatment.
The Role of Drug Safety and Pharmacovigilance in Emerging Women’s Health Therapies
The development of neurokinin receptor antagonists highlights the growing importance of robust safety evaluation and pharmacovigilance in supporting innovation within women’s health. As new non-hormonal therapeutic classes emerge, long-term safety monitoring, benefit–risk assessment, and regulatory oversight remain essential to ensuring sustained patient confidence and therapeutic success.
Careful evaluation of adverse effects, tolerability profiles, and post-marketing safety data continues to play a central role in advancing mechanism-based therapies for menopausal vasomotor symptoms and other women’s health conditions.
Organizations supporting innovative therapies often require integrated pharmacovigilance and medical writing expertise, like that provided by Baupharma, to maintain regulatory compliance, support safety monitoring activities, and strengthen scientific communication throughout the product lifecycle.
